

CHAPTER 6: REFERENCES

- Albert, J., Gaines, H., Sonnerborg, A., Nystrom, G., Pehrson, P. O., Chiodi, F., von Sydow, M., Moberg, L., Lidman, K., Christensson, B., and et al. (1987). Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. *J Med Virol* **23**(1), 67-73.
- Allaway, G. P., Davis-Bruno, K. L., Beaudry, G. A., Garcia, E. B., Wong, E. L., Ryder, A. M., Hasel, K. W., Gauduin, M. C., Koup, R. A., McDougal, J. S., and et al. (1995). Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. *AIDS Res Hum Retroviruses* **11**(5), 533-9.
- Amit, A. G., Mariuzza, R. A., Phillips, S. E., and Poljak, R. J. (1986). Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. *Science* **233**(4765), 747-53.
- Armstrong, S. J., McInerney, T. L., McLain, L., Wahren, B., Hinkula, J., Levi, M., and Dimmock, N. J. (1996). Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. *J Gen Virol* **77** (Pt 12), 2931-41.
- Arthur, L. O., Bess, J. W., Jr., Sowder, R. C., 2nd, Benveniste, R. E., Mann, D. L., Chermann, J. C., and Henderson, L. E. (1992). Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. *Science* **258**(5090), 1935-8.
- Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debre, P., and Leibowitch, J. (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. *Science* **277**(5322), 112-6.
- Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K., and Fujino, M. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. *Proc Natl Acad Sci U S A* **96**(10), 5698-703.
- Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T. C., and Ruprecht, R. M. (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. *Nat Med* **6**(2), 200-6.
- Barbas, C. F., 3rd, Bjorling, E., Chiodi, F., Dunlop, N., Cababa, D., Jones, T. M., Zebedee, S. L., Persson, M. A., Nara, P. L., Norrby, E., and et al. (1992a). Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. *Proc Natl Acad Sci U S A* **89**(19), 9339-43.
- Barbas, C. F., 3rd, Crowe, J. E., Jr., Cababa, D., Jones, T. M., Zebedee, S. L., Murphy, B. R., Chanock, R. M., and Burton, D. R. (1992b). Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. *Proc Natl Acad Sci U S A* **89**(21), 10164-8.

- Barbas, C. F., 3rd, Kang, A. S., Lerner, R. A., and Benkovic, S. J. (1991). Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. *Proc Natl Acad Sci U S A* **88**(18), 7978-82.
- Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* **220**(4599), 868-71.
- Basmaciogullari, S., Babcock, G. J., Van Ryk, D., Wojtowicz, W., and Sodroski, J. (2002). Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. *J Virol* **76**(21), 10791-800.
- Beaumont, T., Quakkelaar, E., van Nuenen, A., Pantophlet, R., and Schuitemaker, H. (2004). Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. *J Virol* **78**(11), 5651-7.
- Berger, E. A., Murphy, P. M., and Farber, J. M. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. *Annu Rev Immunol* **17**, 657-700.
- Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., and Eichberg, J. W. (1990). Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. *Nature* **345**(6276), 622-5.
- Bernstein, H. B., Tucker, S. P., Hunter, E., Schutzbach, J. S., and Compans, R. W. (1994). Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. *J Virol* **68**(1), 463-8.
- Binley, J., and Moore, J. P. (1997). HIV-cell fusion. The viral mousetrap. *Nature* **387**(6631), 346-8.
- Binley, J. M., Ditzel, H. J., Barbas, C. F., 3rd, Sullivan, N., Sodroski, J., Parren, P. W., and Burton, D. R. (1996). Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. *AIDS Res Hum Retroviruses* **12**(10), 911-24.
- Binley, J. M., Klasse, P. J., Cao, Y., Jones, I., Markowitz, M., Ho, D. D., and Moore, J. P. (1997). Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. *J Virol* **71**(4), 2799-809.
- Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C. J., and Burton, D. R. (2004). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. *J Virol* **78**(23), 13232-52.
- Birx, D. L., Redfield, R. R., and Tosato, G. (1986). Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. *N Engl J Med* **314**(14), 874-9.
- Bjorndal, A., Deng, H., Jansson, M., Fiore, J. R., Colognesi, C., Karlsson, A., Albert, J., Scarlatti, G., Littman, D. R., and Fenyo, E. M. (1997). Coreceptor usage of primary

- human immunodeficiency virus type 1 isolates varies according to biological phenotype. *J Virol* **71**(10), 7478-87.
- Blankson, J. N., Persaud, D., and Siliciano, R. F. (2002). The challenge of viral reservoirs in HIV-1 infection. *Annu Rev Med* **53**, 557-93.
- Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J., and Springer, T. A. (1996a). The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* **382**(6594), 829-33.
- Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., and Springer, T. A. (1996b). A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). *J Exp Med* **184**(3), 1101-9.
- Boots, L. J., McKenna, P. M., Arnold, B. A., Keller, P. M., Gorny, M. K., Zolla-Pazner, S., Robinson, J. E., and Conley, A. J. (1997). Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. *AIDS Res Hum Retroviruses* **13**(18), 1549-59.
- Boshoff, C., and Weiss, R. (2002). AIDS-related malignancies. *Nat Rev Cancer* **2**(5), 373-82.
- Bou-Habib, D. C., Roderiquez, G., Oravec, T., Berman, P. W., Lusso, P., and Norcross, M. A. (1994). Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. *J Virol* **68**(9), 6006-13.
- Boyd, M. R., Gustafson, K. R., McMahan, J. B., Shoemaker, R. H., O'Keefe, B. R., Mori, T., Gulakowski, R. J., Wu, L., Rivera, M. I., Laurencot, C. M., Currens, M. J., Cardellina, J. H., 2nd, Buckheit, R. W., Jr., Nara, P. L., Pannell, L. K., Sowder, R. C., 2nd, and Henderson, L. E. (1997). Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. *Antimicrob Agents Chemother* **41**(7), 1521-30.
- Boyer, J. D., Chattergoon, M., Shah, A., Ginsberg, R., MacGregor, R. R., and Weiner, D. B. (1998). HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. *Dev Biol Stand* **95**, 147-53.
- Boyer, J. D., Cohen, A. D., Vogt, S., Schumann, K., Nath, B., Ahn, L., Lacy, K., Bagarazzi, M. L., Higgins, T. J., Baine, Y., Ciccarelli, R. B., Ginsberg, R. S., MacGregor, R. R., and Weiner, D. B. (2000). Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. *J Infect Dis* **181**(2), 476-83.
- Bredell, H., Williamson, C., Sonnenberg, P., Martin, D. J., and Morris, L. (1998). Genetic characterization of HIV type 1 from migrant workers in three South African gold mines. *AIDS Res Hum Retroviruses* **14**(8), 677-84.
- Brodie, S. J., Lewinsohn, D. A., Patterson, B. K., Jiyamapa, D., Krieger, J., Corey, L., Greenberg, P. D., and Riddell, S. R. (1999). In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. *Nat Med* **5**(1), 34-41.
- Brown, K. D., Hostager, B. S., and Bishop, G. A. (2001). Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). *J Exp Med* **193**(8), 943-54.

- Buchacher, A., Predl, R., Strutzenberger, K., Steinfellner, W., Trkola, A., Purtscher, M., Gruber, G., Tauer, C., Steindl, F., Jungbauer, A., and et al. (1994). Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. *AIDS Res Hum Retroviruses* **10**(4), 359-69.
- Buchbinder, S. P., Katz, M. H., Hessol, N. A., O'Malley, P. M., and Holmberg, S. D. (1994). Long-term HIV-1 infection without immunologic progression. *Aids* **8**(8), 1123-8.
- Bures, R., Morris, L., Williamson, C., Ramjee, G., Deers, M., Fiscus, S. A., Abdool-Karim, S., and Montefiori, D. C. (2002). Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. *J Virol* **76**(5), 2233-44.
- Burton, D. R. (1997). A vaccine for HIV type 1: the antibody perspective. *Proc Natl Acad Sci U S A* **94**(19), 10018-23.
- Burton, D. R., Barbas, C. F., 3rd, Persson, M. A., Koenig, S., Chanock, R. M., and Lerner, R. A. (1991). A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. *Proc Natl Acad Sci U S A* **88**(22), 10134-7.
- Burton, D. R., and Montefiori, D. C. (1997). The antibody response in HIV-1 infection. *Aids* **11 Suppl A**, S87-98.
- Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., and et al. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. *Science* **266**(5187), 1024-7.
- Cantin, R., Fortin, J. F., and Tremblay, M. (1996). The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific. *Virology* **218**(2), 372-81.
- Cao, H., Kaleebu, P., Hom, D., Flores, J., Agrawal, D., Jones, N., Serwanga, J., Okello, M., Walker, C., Sheppard, H., El-Habib, R., Klein, M., Mbidde, E., Mugenyi, P., Walker, B., Ellner, J., and Mugerwa, R. (2003). Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. *J Infect Dis* **187**(6), 887-95.
- Casali, P., and Schettino, E. W. (1996). Structure and function of natural antibodies. *Curr Top Microbiol Immunol* **210**, 167-79.
- Cavacini, L. A., Emes, C. L., Power, J., Buchbinder, A., Zolla-Pazner, S., and Posner, M. R. (1993). Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. *J Acquir Immune Defic Syndr* **6**(4), 353-8.
- Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997). Core structure of gp41 from the HIV envelope glycoprotein. *Cell* **89**(2), 263-73.
- Chan, D. C., and Kim, P. S. (1998). HIV entry and its inhibition. *Cell* **93**(5), 681-4.
- Chen, C. H., Jin, L., Zhu, C., Holz-Smith, S., and Matthews, T. J. (2001). Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. *J Virol* **75**(14), 6700-4.
- Choe, H., Li, W., Wright, P. L., Vasilieva, N., Venturi, M., Huang, C. C., Grundner, C., Dorfman, T., Zwick, M. B., Wang, L., Rosenberg, E. S., Kwong, P. D., Burton, D. R.,

- Robinson, J. E., Sodroski, J. G., and Farzan, M. (2003). Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. *Cell* **114**(2), 161-70.
- Cilliers, T., Nhlapo, J., Coetzer, M., Orlovic, D., Ketas, T., Olson, W. C., Moore, J. P., Trkola, A., and Morris, L. (2003). The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. *J Virol* **77**(7), 4449-56.
- Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P. (1995). Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. *Science* **270**(5243), 1811-5.
- Cole, K. S., Alvarez, M., Elliott, D. H., Lam, H., Martin, E., Chau, T., Micken, K., Rowles, J. L., Clements, J. E., Murphey-Corb, M., Montelaro, R. C., and Robinson, J. E. (2001). Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. *Virology* **290**(1), 59-73.
- Colman, P. M. (1988). Structure of antibody-antigen complexes: implications for immune recognition. *Adv Immunol* **43**, 99-132.
- Connor, R. I., Korber, B. T., Graham, B. S., Hahn, B. H., Ho, D. D., Walker, B. D., Neumann, A. U., Vermund, S. H., Mestecky, J., Jackson, S., Fenamore, E., Cao, Y., Gao, F., Kalams, S., Kunstman, K. J., McDonald, D., McWilliams, N., Trkola, A., Moore, J. P., and Wolinsky, S. M. (1998). Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. *J Virol* **72**(2), 1552-76.
- Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., and Landau, N. R. (1997). Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. *J Exp Med* **185**(4), 621-8.
- Cormier, E. G., and Dragic, T. (2002). The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. *J Virol* **76**(17), 8953-7.
- Cornelissen, M., Mulder-Kampinga, G., Veenstra, J., Zorgdrager, F., Kuiken, C., Hartman, S., Dekker, J., van der Hoek, L., Sol, C., Coutinho, R., and et al. (1995). Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. *J Virol* **69**(3), 1810-8.
- Dacheux, L., Moreau, A., Ataman-Onal, Y., Biron, F., Verrier, B., and Barin, F. (2004). Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. *J Virol* **78**(22), 12625-37.
- D'Costa, S., Slobod, K. S., Webster, R. G., White, S. W., and Hurwitz, J. L. (2001). Structural features of HIV envelope defined by antibody escape mutant analysis. *AIDS Res Hum Retroviruses* **17**(12), 1205-9.
- de Wolf, F., Spijkerman, I., Schellekens, P. T., Langendam, M., Kuiken, C., Bakker, M., Roos, M., Coutinho, R., Miedema, F., and Goudsmit, J. (1997). AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. *Aids* **11**(15), 1799-806.

- Dey, B., Del Castillo, C. S., and Berger, E. A. (2003). Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. *J Virol* **77**(5), 2859-65.
- Dittmer, U., Brooks, D. M., and Hasenkrug, K. J. (1998). Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. *J Virol* **72**(8), 6554-8.
- Ditzel, H. J., Binley, J. M., Moore, J. P., Sodroski, J., Sullivan, N., Sawyer, L. S., Hendry, R. M., Yang, W. P., Barbas, C. F., 3rd, and Burton, D. R. (1995). Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. *J Immunol* **154**(2), 893-906.
- Ditzel, H. J., Itoh, K., and Burton, D. R. (1996). Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. *J Immunol* **157**(2), 739-49.
- Dorsky, D. I., and Harrington, R. D. (1999). An indicator cell assay for T-cell tropic, macrophage-tropic, and primary isolates of HIV-1 based on green fluorescent protein. *J Acquir Immune Defic Syndr* **22**(3), 213-20.
- Douek, D. C., Brenchley, J. M., Betts, M. R., Ambrozak, D. R., Hill, B. J., Okamoto, Y., Casazza, J. P., Kuruppu, J., Kunstman, K., Wolinsky, S., Grossman, Z., Dybul, M., Oxenius, A., Price, D. A., Connors, M., and Koup, R. A. (2002). HIV preferentially infects HIV-specific CD4+ T cells. *Nature* **417**(6884), 95-8.
- Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature* **381**(6584), 667-73.
- Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., and Moore, J. P. (2000). A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. *Proc Natl Acad Sci U S A* **97**(10), 5639-44.
- D'Souza, M. P., Geyer, S. J., Hanson, C. V., Hendry, R. M., and Milman, G. (1994). Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration. *Aids* **8**(2), 169-81.
- Esser, M. T., Mori, T., Mondor, I., Sattentau, Q. J., Dey, B., Berger, E. A., Boyd, M. R., and Lifson, J. D. (1999). Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. *J Virol* **73**(5), 4360-71.
- Farzan, M., Vasilieva, N., Schnitzler, C. E., Chung, S., Robinson, J., Gerard, N. P., Gerard, C., Choe, H., and Sodroski, J. (2000). A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. *J Biol Chem* **275**(43), 33516-21.
- Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* **272**(5263), 872-7.
- Ferrantelli, F., and Ruprecht, R. M. (2002). Neutralizing antibodies against HIV back in the major leagues? *Curr Opin Immunol* **14**(4), 495-502.

- Forthal, D. N., Landucci, G., Gorny, M. K., Zolla-Pazner, S., and Robinson, W. E., Jr. (1995). Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. *AIDS Res Hum Retroviruses* **11**(9), 1095-9.
- Fouts, T. R., Binley, J. M., Trkola, A., Robinson, J. E., and Moore, J. P. (1997). Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. *J Virol* **71**(4), 2779-85.
- French, D. L., Laskov, R., and Scharff, M. D. (1989). The role of somatic hypermutation in the generation of antibody diversity. *Science* **244**(4909), 1152-7.
- Fultz, P. N. (1992). Immunization and challenge of chimpanzees with HIV-1. *AIDS Res Hum Retroviruses* **8**(8), 1517-9.
- Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., Kaplan, M., Haynes, B. F., Palker, T. J., Redfield, R., Oleske, J., Safai, B., and et al. (1984). Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* **224**(4648), 500-3.
- Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H., Bhattacharya, T., and Korber, B. (2002). Diversity considerations in HIV-1 vaccine selection. *Science* **296**(5577), 2354-60.
- Geoffroy, F., Sodoyer, R., and Aujame, L. (1994). A new phage display system to construct multicombinatorial libraries of very large antibody repertoires. *Gene* **151**(1-2), 109-13.
- Gorny, M. K., Conley, A. J., Karwowska, S., Buchbinder, A., Xu, J. Y., Emini, E. A., Koenig, S., and Zolla-Pazner, S. (1992). Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. *J Virol* **66**(12), 7538-42.
- Gorny, M. K., Gianakakos, V., Sharpe, S., and Zolla-Pazner, S. (1989). Generation of human monoclonal antibodies to human immunodeficiency virus. *Proc Natl Acad Sci U S A* **86**(5), 1624-8.
- Gorny, M. K., Mascola, J. R., Israel, Z. R., VanCott, T. C., Williams, C., Balfe, P., Hioe, C., Brodine, S., Burda, S., and Zolla-Pazner, S. (1998). A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. *AIDS Res Hum Retroviruses* **14**(3), 213-21.
- Gorny, M. K., Williams, C., Volsky, B., Revesz, K., Cohen, S., Polonis, V. R., Honnen, W. J., Kayman, S. C., Krachmarov, C., Pinter, A., and Zolla-Pazner, S. (2002). Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. *J Virol* **76**(18), 9035-45.
- Gottlieb, G. J., Ragaz, A., Vogel, J. V., Friedman-Kien, A., Rywlin, A. M., Weiner, E. A., and Ackerman, A. B. (1981a). A preliminary communication on extensively disseminated Kaposi's sarcoma in young homosexual men. *Am J Dermatopathol* **3**(2), 111-4.
- Gottlieb, M. S., Schroff, R., Schanker, H. M., Weisman, J. D., Fan, P. T., Wolf, R. A., and Saxon, A. (1981b). Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. *N Engl J Med* **305**(24), 1425-31.

- Graham, B. S., and Mascola, J. R. (2005). Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. *J Infect Dis* **191**(5), 647-9.
- Graham, B. S., McElrath, M. J., Connor, R. I., Schwartz, D. H., Gorse, G. J., Keefer, M. C., Mulligan, M. J., Matthews, T. J., Wolinsky, S. M., Montefiori, D. C., Vermund, S. H., Lambert, J. S., Corey, L., Belshe, R. B., Dolin, R., Wright, P. F., Korber, B. T., Wolff, M. C., and Fast, P. E. (1998). Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. *J Infect Dis* **177**(2), 310-9.
- Guigou, V., Guilbert, B., Moinier, D., Tonnelle, C., Boubli, L., Avrameas, S., Fougereau, M., and Fumoux, F. (1991). Ig repertoire of human polyspecific antibodies and B cell ontogeny. *J Immunol* **146**(4), 1368-74.
- Guo, Q., Ho, H. T., Dicker, I., Fan, L., Zhou, N., Friborg, J., Wang, T., McAuliffe, B. V., Wang, H. G., Rose, R. E., Fang, H., Scarnati, H. T., Langley, D. R., Meanwell, N. A., Abraham, R., Colonno, R. J., and Lin, P. F. (2003). Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. *J Virol* **77**(19), 10528-36.
- Haase, A. T. (1999). Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. *Annu Rev Immunol* **17**, 625-56.
- Hart, T. K., Kirsh, R., Ellens, H., Sweet, R. W., Lambert, D. M., Petteway, S. R., Jr., Leary, J., and Bugelski, P. J. (1991). Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. *Proc Natl Acad Sci U S A* **88**(6), 2189-93.
- Haynes, B. F., Fleming, J., St Clair, W. E., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Scarce, R. M., Plonk, K., Staats, H. F., Ortel, T. L., Liao, H. X., and Alam, M. S. (2005). Cardiophilin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. *Science*.
- Helseth, E., Olshevsky, U., Furman, C., and Sodroski, J. (1991). Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. *J Virol* **65**(4), 2119-23.
- Hessol, N. A., and Palacio, H. (1996). Gender, ethnicity and transmission category variation in HIV disease progression. *Aids* **10 Suppl A**, S69-74.
- Hill, C. M., Deng, H., Unutmaz, D., Kewalramani, V. N., Bastiani, L., Gorny, M. K., Zolla-Pazner, S., and Littman, D. R. (1997). Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. *J Virol* **71**(9), 6296-304.
- Hioe, C. E., Xu, S., Chigurupati, P., Burda, S., Williams, C., Gorny, M. K., and Zolla-Pazner, S. (1997). Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. *Int Immunol* **9**(9), 1281-90.
- Hogervorst, E., de Jong, J., van Wijk, A., Bakker, M., Valk, M., Nara, P., and Goudsmit, J. (1995). Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies. *J Virol* **69**(10), 6342-51.

- Hoxie, J. A., Fitzharris, T. P., Youngbar, P. R., Matthews, D. M., Rackowski, J. L., and Radka, S. F. (1987). Nonrandom association of cellular antigens with HTLV-III virions. *Hum Immunol* **18**(1), 39-52.
- <http://hiv-web.lanl.gov>
<http://www-immuno.path.cam.ac.uk>
<http://www.labcorp.com>
<http://www.unaids.org>
- Hung, C. S., Vander Heyden, N., and Ratner, L. (1999). Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. *J Virol* **73**(10), 8216-26.
- Ivanoff, L. A., Dubay, J. W., Morris, J. F., Roberts, S. J., Gutshall, L., Sternberg, E. J., Hunter, E., Matthews, T. J., and Petteway, S. R., Jr. (1992). V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. *Virology* **187**(2), 423-32.
- Jacobson, M. A., and French, M. (1998). Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. *Aids* **12 Suppl A**, S157-63.
- Jeffs, S. A., McKeating, J., Lewis, S., Craft, H., Biram, D., Stephens, P. E., and Brady, R. L. (1996). Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. *J Gen Virol* **77** (Pt 7), 1403-10.
- Jeffs, S. A., Shotton, C., Balfe, P., and McKeating, J. A. (2002). Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. *J Gen Virol* **83**(Pt 11), 2723-32.
- Karlsson, A., Parsmyr, K., Aperia, K., Sandstrom, E., Fenyo, E. M., and Albert, J. (1994). MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. *J Infect Dis* **170**(6), 1367-75.
- Kent, K. A., and Robinson, J. (1996). Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist. *Aids* **10 Suppl A**, S107-14.
- Klasse, P. J., and Moore, J. P. (1996). Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. *J Virol* **70**(6), 3668-77.
- Klasse, P. J., and Sattentau, Q. J. (2002). Occupancy and mechanism in antibody-mediated neutralization of animal viruses. *J Gen Virol* **83**(Pt 9), 2091-108.
- Kolchinsky, P., Mirzabekov, T., Farzan, M., Kiprilov, E., Cayabyab, M., Mooney, L. J., Choe, H., and Sodroski, J. (1999). Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. *J Virol* **73**(10), 8120-6.
- Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., and Ho, D. D. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* **68**(7), 4650-5.
- Kovacs, J. A., Bechtel, C., Davey, R. T., Jr., Falloon, J., Polis, M. A., Walker, R. E., Metcalf, J. A., Davey, V., Piscitelli, S. C., Baseler, M., Dewar, R., Salzman, N. P., Masur, H., and Lane, H. C. (1996). Combination therapy with didanosine and interferon-alpha in

- human immunodeficiency virus-infected patients: results of a phase I/II trial. *J Infect Dis* **173**(4), 840-8.
- Kuhmann, S. E., Pugach, P., Kunstman, K. J., Taylor, J., Stanfield, R. L., Snyder, A., Strizki, J. M., Riley, J., Baroudy, B. M., Wilson, I. A., Korber, B. T., Wolinsky, S. M., and Moore, J. P. (2004). Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. *J Virol* **78**(6), 2790-807.
- Kuppers, R. (2003a). B cells under influence: transformation of B cells by Epstein-Barr virus. *Nat Rev Immunol* **3**(10), 801-12.
- Kuppers, R. (2003b). Somatic hypermutation and B cell receptor selection in normal and transformed human B cells. *Ann N Y Acad Sci* **987**, 173-9.
- Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* **393**(6686), 648-59.
- Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J., and Hendrickson, W. A. (2000). Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. *J Virol* **74**(4), 1961-72.
- Laal, S., Burda, S., Gorny, M. K., Karwowska, S., Buchbinder, A., and Zolla-Pazner, S. (1994). Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. *J Virol* **68**(6), 4001-8.
- Labrosse, B., Brelot, A., Heveker, N., Sol, N., Schols, D., De Clercq, E., and Alizon, M. (1998). Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. *J Virol* **72**(8), 6381-8.
- LaCasse, R. A., Follis, K. E., Moudgil, T., Trahey, M., Binley, J. M., Planelles, V., Zolla-Pazner, S., and Nunberg, J. H. (1998). Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. *J Virol* **72**(3), 2491-5.
- Lamers, S. L., Sleasman, J. W., She, J. X., Barrie, K. A., Pomeroy, S. M., Barrett, D. J., and Goodenow, M. M. (1993). Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. *J Virol* **67**(7), 3951-60.
- LaRosa, G. J., Davide, J. P., Weinhold, K., Waterbury, J. A., Profy, A. T., Lewis, J. A., Langlois, A. J., Dreesman, G. R., Boswell, R. N., Shadduck, P., and et al. (1990). Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. *Science* **249**(4971), 932-5.
- Lee, W. R., Syu, W. J., Du, B., Matsuda, M., Tan, S., Wolf, A., Essex, M., and Lee, T. H. (1992). Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A* **89**(6), 2213-7.
- Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., and Gregory, T. J. (1990). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. *J Biol Chem* **265**(18), 10373-82.
- Letvin, N. L., and Walker, B. D. (2003). Immunopathogenesis and immunotherapy in AIDS virus infections. *Nat Med* **9**(7), 861-6.
- Lewin, B. 1994. Genes IV. Oxford University Press. Oxford.

- Li, A., Katinger, H., Posner, M. R., Cavacini, L., Zolla-Pazner, S., Gorny, M. K., Sodroski, J., Chou, T. C., Baba, T. W., and Ruprecht, R. M. (1998). Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. *J Virol* **72**(4), 3235-40.
- Li, Y., Luo, L., Rasool, N., and Kang, C. Y. (1993). Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. *J Virol* **67**(1), 584-8.
- Liesveld, J. L., Rush, S., Kempinski, M. C., Turner, A. R., Brennan, J. K., Gasson, J. C., and Abboud, C. N. (1993). Phenotypic characterization of the human fibrous histiocytoma giant cell tumor (GCT) cell line and its cytokine repertoire. *Exp Hematol* **21**(10), 1342-52.
- Linsley, P. S., Ledbetter, J. A., Kinney-Thomas, E., and Hu, S. L. (1988). Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. *J Virol* **62**(10), 3695-702.
- Little, S. J., McLean, A. R., Spina, C. A., Richman, D. D., and Havlir, D. V. (1999). Viral dynamics of acute HIV-1 infection. *J Exp Med* **190**(6), 841-50.
- Losman, B., Bolmstedt, A., Schonning, K., Bjorndal, A., Westin, C., Fenyo, E. M., and Olofsson, S. (2001). Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. *AIDS Res Hum Retroviruses* **17**(11), 1067-76.
- Louwagie, J., McCutchan, F. E., Peeters, M., Brennan, T. P., Sanders-Buell, E., Eddy, G. A., van der Groen, G., Fransen, K., Gershby-Damet, G. M., Deleys, R., and et al. (1993). Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. *Aids* **7**(6), 769-80.
- Lu, S., Putney, S. D., and Robinson, H. L. (1992). Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. *J Virol* **66**(4), 2547-50.
- Lubeck, M. D., Natuk, R., Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, S. C., Chanda, P. K., Nigida, S. M., Jr., Markham, P. D., Zolla-Pazner, S., Steimer, K., Wade, M., Reitz, M. S., Jr., Arthur, L. O., Mizutani, S., Davis, A., Hung, P. P., Gallo, R. C., Eichberg, J., and Robert-Guroff, M. (1997). Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. *Nat Med* **3**(6), 651-8.
- Mackewicz, C. E., Yang, L. C., Lifson, J. D., and Levy, J. A. (1994). Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. *Lancet* **344**(8938), 1671-3.
- Mascola, J. R., Frankel, S. S., and Broliden, K. (2000). HIV-1 entry at the mucosal surface: role of antibodies in protection. *Aids* **14 Suppl 3**, S167-74.
- Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. S., Muenz, L. R., Bunow, B., Birx, D. L., and Robb, M. L. (1997). Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. *J Virol* **71**(10), 7198-206.
- Mascola, J. R., Louder, M. K., Winter, C., Prabhakara, R., De Rosa, S. C., Douek, D. C., Hill, B. J., Gabuzda, D., and Roederer, M. (2002). Human immunodeficiency virus type 1

- neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. *J Virol* **76**(10), 4810-21.
- Mascola, J. R., Mathieson, B. J., Zack, P. M., Walker, M. C., Halstead, S. B., and Burke, D. S. (1993). Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. *AIDS Res Hum Retroviruses* **9**(12), 1175-84.
- Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., and Lewis, M. G. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. *Nat Med* **6**(2), 207-10.
- McCafferty, J., Griffiths, A. D., Winter, G., and Chiswell, D. J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. *Nature* **348**(6301), 552-4.
- McKeating, J. A., Cordell, J., Dean, C. J., and Balfe, P. (1992). Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. *Virology* **191**(2), 732-42.
- McMichael, A., Mwau, M., and Hanke, T. (2002). Design and tests of an HIV vaccine. *Br Med Bull* **62**, 87-98.
- McMichael, A. J., and Hanke, T. (2003). HIV vaccines 1983-2003. *Nat Med* **9**(7), 874-80.
- Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., and Rinaldo, C. R., Jr. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* **126**(12), 946-54.
- Mellors, J. W., Rinaldo, C. R., Jr., Gupta, P., White, R. M., Todd, J. A., and Kingsley, L. A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science* **272**(5265), 1167-70.
- Miller, C. L., Burkhardt, A. L., Lee, J. H., Stealey, B., Longnecker, R., Bolen, J. B., and Kieff, E. (1995). Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. *Immunity* **2**(2), 155-66.
- Montagnier, L., Chermann, J. C., Barre-Sinoussi, F., Klatzmann, D., Wain-Hobson, S., Alizon, M., Clavel, F., Brun-Vezinet, F., Vilmer, E., Rouzioux, C., and et al. (1984). Lymphadenopathy associated virus and its etiological role in AIDS. *Princess Takamatsu Symp* **15**, 319-31.
- Moore, J. P., and Burton, D. R. (2004). Urgently needed: a filter for the HIV-1 vaccine pipeline. *Nat Med* **10**(8), 769-71.
- Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B., and Ho, D. D. (1996). Inter- and intracade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. *J Virol* **70**(1), 427-44.
- Moore, J. P., and Ho, D. D. (1995). HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. *Aids* **9 Suppl A**, S117-36.
- Moore, J. P., McCutchan, F. E., Poon, S. W., Mascola, J., Liu, J., Cao, Y., and Ho, D. D. (1994). Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. *J Virol* **68**(12), 8350-64.

- Moore, J. P., McKeating, J. A., Norton, W. A., and Sattentau, Q. J. (1991). Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. *J Virol* **65**(3), 1133-40.
- Moore, J. P., McKeating, J. A., Weiss, R. A., and Sattentau, Q. J. (1990). Dissociation of gp120 from HIV-1 virions induced by soluble CD4. *Science* **250**(4984), 1139-42.
- Moore, J. P., and Nara, P. L. (1991). The role of the V3 loop of gp120 in HIV infection. *Aids* **5 Suppl 2**, S21-33.
- Moore, J. P., and Sodroski, J. (1996). Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. *J Virol* **70**(3), 1863-72.
- Morris, L., Binley, J. M., Clas, B. A., Bonhoeffer, S., Astill, T. P., Kost, R., Hurley, A., Cao, Y., Markowitz, M., Ho, D. D., and Moore, J. P. (1998). HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. *J Exp Med* **188**(2), 233-45.
- Moulard, M., Phogat, S. K., Shu, Y., Labrijn, A. F., Xiao, X., Binley, J. M., Zhang, M. Y., Sidorov, I. A., Broder, C. C., Robinson, J., Parren, P. W., Burton, D. R., and Dimitrov, D. S. (2002). Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. *Proc Natl Acad Sci U S A* **99**(10), 6913-8.
- Muster, T., Ferko, B., Klima, A., Purtscher, M., Trkola, A., Schulz, P., Grassauer, A., Engelhardt, O. G., Garcia-Sastre, A., Palese, P., and et al. (1995). Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. *J Virol* **69**(11), 6678-86.
- Muster, T., Guinea, R., Trkola, A., Purtscher, M., Klima, A., Steindl, F., Palese, P., and Katinger, H. (1994). Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. *J Virol* **68**(6), 4031-4.
- Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rucker, F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. *J Virol* **67**(11), 6642-7.
- Nabatov, A. A., Pollakis, G., Linnemann, T., Kliphuis, A., Chalaby, M. I., and Paxton, W. A. (2004). Inpatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. *J Virol* **78**(1), 524-30.
- Nakayama, T., Fujisawa, R., Izawa, D., Hieshima, K., Takada, K., and Yoshie, O. (2002). Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCR4 and CXCR5. *J Virol* **76**(6), 3072-7.
- Nyambi, P. N., Gorny, M. K., Bastiani, L., van der Groen, G., Williams, C., and Zolla-Pazner, S. (1998). Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. *J Virol* **72**(11), 9384-91.
- Nyambi, P. N., Mbah, H. A., Burda, S., Williams, C., Gorny, M. K., Nadas, A., and Zolla-Pazner, S. (2000a). Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. *J Virol* **74**(15), 7096-107.

- Nyambi, P. N., Nadas, A., Mbah, H. A., Burda, S., Williams, C., Gorny, M. K., and Zolla-Pazner, S. (2000b). Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. *J Virol* **74**(22), 10670-80.
- Ohgimoto, S., Shioda, T., Mori, K., Nakayama, E. E., Hu, H., and Nagai, Y. (1998). Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity. *J Virol* **72**(10), 8365-70.
- Olson, W. C., Rabut, G. E., Nagashima, K. A., Tran, D. N., Anselma, D. J., Monard, S. P., Segal, J. P., Thompson, D. A., Kajumo, F., Guo, Y., Moore, J. P., Maddon, P. J., and Dragic, T. (1999). Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. *J Virol* **73**(5), 4145-55.
- Orentas, R. J., and Hildreth, J. E. (1993). Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. *AIDS Res Hum Retroviruses* **9**(11), 1157-65.
- Pal, R., Hoke, G. M., and Sarngadharan, M. G. (1989). Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A* **86**(9), 3384-8.
- Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P. W., Wilson, I. A., and Burton, D. R. (2003). Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. *J Virol* **77**(1), 642-58.
- Parmley, S. F., and Smith, G. P. (1988). Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. *Gene* **73**(2), 305-18.
- Parren, P. W., and Burton, D. R. (2001). The antiviral activity of antibodies in vitro and in vivo. *Adv Immunol* **77**, 195-262.
- Parren, P. W., Burton, D. R., and Sattentau, Q. J. (1997). HIV-1 antibody--debris or virion? *Nat Med* **3**(4), 366-7.
- Parren, P. W., Ditzel, H. J., Gulizia, R. J., Binley, J. M., Barbas, C. F., 3rd, Burton, D. R., and Mosier, D. E. (1995). Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. *Aids* **9**(6), F1-6.
- Parren, P. W., Gauduin, M. C., Koup, R. A., Poignard, P., Fiscicaro, P., Burton, D. R., and Sattentau, Q. J. (1997a). Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. *Immunol Lett* **57**(1-3), 105-12.
- Parren, P. W., Gauduin, M. C., Koup, R. A., Poignard, P., Sattentau, Q. J., Fiscicaro, P., and Burton, D. R. (1997b). Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design". *Immunol Lett* **58**(2), 125-32.
- Parren, P. W., Marx, P. A., Hessel, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., and Burton, D. R. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. *J Virol* **75**(17), 8340-7.

- Parren, P. W., Mondor, I., Naniche, D., Ditzel, H. J., Klasse, P. J., Burton, D. R., and Sattentau, Q. J. (1998a). Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. *J Virol* **72**(5), 3512-9.
- Parren, P. W., Moore, J. P., Burton, D. R., and Sattentau, Q. J. (1999). The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. *Aids* **13 Suppl A**, S137-62.
- Parren, P. W., Poignard, P., Ditzel, H. J., Williamson, R. A., and Burton, D. R. (2000). Antibodies in human infectious disease. *Immunol Res* **21**(2-3), 265-78.
- Parren, P. W., Wang, M., Trkola, A., Binley, J. M., Purtscher, M., Katinger, H., Moore, J. P., and Burton, D. R. (1998b). Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. *J Virol* **72**(12), 10270-4.
- Peeters, M., Toure-Kane, C., and Nkengasong, J. N. (2003). Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. *Aids* **17**(18), 2547-60.
- Pelchen-Matthews, A., Clapham, P., and Marsh, M. (1995). Role of CD4 endocytosis in human immunodeficiency virus infection. *J Virol* **69**(12), 8164-8.
- Pilgrim, A. K., Pantaleo, G., Cohen, O. J., Fink, L. M., Zhou, J. Y., Zhou, J. T., Bolognesi, D. P., Fauci, A. S., and Montefiori, D. C. (1997). Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. *J Infect Dis* **176**(4), 924-32.
- Pinter, A., Honnen, W. J., and Tilley, S. A. (1993). Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. *J Virol* **67**(9), 5692-7.
- Poignard, P., Sabbe, R., Picchio, G. R., Wang, M., Gulizia, R. J., Katinger, H., Parren, P. W., Mosier, D. E., and Burton, D. R. (1999). Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. *Immunity* **10**(4), 431-8.
- Pope, M., and Haase, A. T. (2003). Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. *Nat Med* **9**(7), 847-52.
- Potts, B. J., Field, K. G., Wu, Y., Posner, M., Cavacini, L., and White-Scharf, M. (1993). Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. *Virology* **197**(1), 415-9.
- Premack, B. A., and Schall, T. J. (1996). Chemokine receptors: gateways to inflammation and infection. *Nat Med* **2**(11), 1174-8.
- Pugach, P., Kuhmann, S. E., Taylor, J., Marozsan, A. J., Snyder, A., Ketas, T., Wolinsky, S. M., Korber, B. T., and Moore, J. P. (2004). The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. *Virology* **321**(1), 8-22.
- Purtscher, M., Trkola, A., Grassauer, A., Schulz, P. M., Klima, A., Dopfer, S., Gruber, G., Buchacher, A., Muster, T., and Katinger, H. (1996). Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. *Aids* **10**(6), 587-93.
- Purtscher, M., Trkola, A., Gruber, G., Buchacher, A., Predl, R., Steindl, F., Tauer, C., Berger, R., Barrett, N., Jungbauer, A., and et al. (1994). A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* **10**(12), 1651-8.

- Raja, A., Venturi, M., Kwong, P., and Sodroski, J. (2003). CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. *J Virol* **77**(1), 713-8.
- Rajewsky, K. (1996). Clonal selection and learning in the antibody system. *Nature* **381**(6585), 751-8.
- Richman, D. D., Wrin, T., Little, S. J., and Petropoulos, C. J. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. *Proc Natl Acad Sci U S A* **100**(7), 4144-9.
- Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., and Sodroski, J. (1998). A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. *Science* **280**(5371), 1949-53.
- Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., 3rd, and Burton, D. R. (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. *J Virol* **68**(8), 4821-8.
- Robertson, D. L., Anderson, J. P., Bradac, J. A., Carr, J. K., Foley, B., Funkhouser, R. K., Gao, F., Hahn, B. H., Kalish, M. L., Kuiken, C., Learn, G. H., Leitner, T., McCutchan, F., Osmanov, S., Peeters, M., Pieniazek, D., Salminen, M., Sharp, P. M., Wolinsky, S., and Korber, B. (2000). HIV-1 nomenclature proposal. *Science* **288**(5463), 55-6.
- Robinson, J. E., Cole, K. S., Elliott, D. H., Lam, H., Amedee, A. M., Means, R., Desrosiers, R. C., Clements, J., Montelaro, R. C., and Murphey-Corb, M. (1998). Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptotically infected with a live SIV vaccine. *AIDS Res Hum Retroviruses* **14**(14), 1253-62.
- Robinson, J. E., Holton, D., Pacheco-Morell, S., Liu, J., and McMurdo, H. (1990). Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. *AIDS Res Hum Retroviruses* **6**(5), 567-79.
- Roderiquez, G., Oravec, T., Yanagishita, M., Bou-Habib, D. C., Mostowski, H., and Norcross, M. A. (1995). Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. *J Virol* **69**(4), 2233-9.
- Roitt, I., Brostoff, J., Male, D. 2001. *Immunology* (6th edition). Mosby publishers, London.
- Salahuddin, S. Z., Markham, P. D., Wong-Staal, F., Franchini, G., Kalyanaraman, V. S., and Gallo, R. C. (1983). Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. *Virology* **129**(1), 51-64.
- Salzwedel, K., West, J. T., and Hunter, E. (1999). A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. *J Virol* **73**(3), 2469-80.
- Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D., and Moore, J. P. (2002). The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. *J Virol* **76**(14), 7293-305.

- Sattentau, Q. J., and Moore, J. P. (1991). Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. *J Exp Med* **174**(2), 407-15.
- Sattentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. *J Exp Med* **182**(1), 185-96.
- Sattentau, Q. J., Moore, J. P., Vignaux, F., Traincard, F., and Poignard, P. (1993). Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. *J Virol* **67**(12), 7383-93.
- Sawyer, L. S., Wrin, M. T., Crawford-Miksza, L., Potts, B., Wu, Y., Weber, P. A., Alfonso, R. D., and Hanson, C. V. (1994). Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. *J Virol* **68**(3), 1342-9.
- Scanlan, C. N., Pantophlet, R., Wormald, M. R., Ollmann Saphire, E., Stanfield, R., Wilson, I. A., Katinger, H., Dwek, R. A., Rudd, P. M., and Burton, D. R. (2002). The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. *J Virol* **76**(14), 7306-21.
- Sharon, M., Kessler, N., Levy, R., Zolla-Pazner, S., Goralach, M., and Anglister, J. (2003). Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. *Structure (Camb)* **11**(2), 225-36.
- Sheppard, H. W., Lang, W., Ascher, M. S., Vittinghoff, E., and Winkelstein, W. (1993). The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. *Aids* **7**(9), 1159-66.
- Simon, F., Mauclore, P., Roques, P., Loussert-Ajaka, I., Muller-Trutwin, M. C., Saragosti, S., Georges-Courbot, M. C., Barre-Sinoussi, F., and Brun-Vezinet, F. (1998). Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. *Nat Med* **4**(9), 1032-7.
- Skinner, M. A., Langlois, A. J., McDanal, C. B., McDougal, J. S., Bolognesi, D. P., and Matthews, T. J. (1988). Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. *J Virol* **62**(11), 4195-200.
- Smith, S. D., Shatsky, M., Cohen, P. S., Warnke, R., Link, M. P., and Glader, B. E. (1984). Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. *Cancer Res* **44**(12 Pt 1), 5657-60.
- Stamatatos, L., and Cheng-Mayer, C. (1995). Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. *J Virol* **69**(10), 6191-8.
- Starcich, B. R., Hahn, B. H., Shaw, G. M., McNeely, P. D., Modrow, S., Wolf, H., Parks, E. S., Parks, W. P., Josephs, S. F., Gallo, R. C., and et al. (1986). Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. *Cell* **45**(5), 637-48.
- Stiegler, G., Kunert, R., Purtscher, M., Wolbank, S., Voglauer, R., Steindl, F., and Katinger, H. (2001). A potent cross-clade neutralizing human monoclonal antibody against a

- novel epitope on gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* **17**(18), 1757-65.
- Sullivan, N., Sun, Y., Binley, J., Lee, J., Barbas, C. F., 3rd, Parren, P. W., Burton, D. R., and Sodroski, J. (1998a). Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. *J Virol* **72**(8), 6332-8.
- Sullivan, N., Sun, Y., Sattentau, Q., Thali, M., Wu, D., Denisova, G., Gershoni, J., Robinson, J., Moore, J., and Sodroski, J. (1998b). CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. *J Virol* **72**(6), 4694-703.
- Suphaphiphat, P., Thitithanyanont, A., Paca-Uccaralertkun, S., Essex, M., and Lee, T. H. (2003). Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. *J Virol* **77**(6), 3832-7.
- Tamamura, H., Xu, Y., Hattori, T., Zhang, X., Arakaki, R., Kanbara, K., Omagari, A., Otaka, A., Ibuka, T., Yamamoto, N., Nakashima, H., and Fujii, N. (1998). A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. *Biochem Biophys Res Commun* **253**(3), 877-82.
- Thali, M., Furman, C., Ho, D. D., Robinson, J., Tilley, S., Pinter, A., and Sodroski, J. (1992). Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. *J Virol* **66**(9), 5635-41.
- Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J., and Sodroski, J. (1993). Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. *J Virol* **67**(7), 3978-88.
- Thali, M., Olshevsky, U., Furman, C., Gabuzda, D., Posner, M., and Sodroski, J. (1991). Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. *J Virol* **65**(11), 6188-93.
- Tilley, S. A., Honnen, W. J., Racho, M. E., Chou, T. C., and Pinter, A. (1992). Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. *AIDS Res Hum Retroviruses* **8**(4), 461-7.
- Tonegawa, S. (1983). Somatic generation of antibody diversity. *Nature* **302**(5909), 575-81.
- Trkola, A., Dragic, T., Arthos, J., Binley, J. M., Olson, W. C., Allaway, G. P., Cheng-Mayer, C., Robinson, J., Maddon, P. J., and Moore, J. P. (1996a). CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. *Nature* **384**(6605), 184-7.
- Trkola, A., Ketas, T., Kewalramani, V. N., Endorf, F., Binley, J. M., Katinger, H., Robinson, J., Littman, D. R., and Moore, J. P. (1998). Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. *J Virol* **72**(3), 1876-85.
- Trkola, A., Ketas, T. J., Nagashima, K. A., Zhao, L., Cilliers, T., Morris, L., Moore, J. P., Maddon, P. J., and Olson, W. C. (2001). Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. *J Virol* **75**(2), 579-88.

- Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C., Manrique, A., Huber, M., Rehr, M., Oxenius, A., Weber, R., Stiegler, G., Vcelar, B., Katinger, H., Aceto, L., and Gunthard, H. F. (2005). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. *Nat Med* **11**(6), 615-22.
- Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., and Katinger, H. (1996b). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. *J Virol* **70**(2), 1100-8.
- Ugolini, S., Mondor, I., Parren, P. W., Burton, D. R., Tilley, S. A., Klasse, P. J., and Sattentau, Q. J. (1997). Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. *J Exp Med* **186**(8), 1287-98.
- Valenzuela, A., Blanco, J., Krust, B., Franco, R., and Hovanessian, A. G. (1997). Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. *J Virol* **71**(11), 8289-98.
- Van de Peere, P., Lepage, P., Simonon, A., Desgranges, C., Hitimana, D. G., Bazubagira, A., Van Goethem, C., Kleinschmidt, A., Bex, F., Broliden, K., and et al. (1992). Biological markers associated with prolonged survival in African children maternally infected by the human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* **8**(4), 435-42.
- Van Harmelen, J. H., Van der Ryst, E., Loubser, A. S., York, D., Madurai, S., Lyons, S., Wood, R., and Williamson, C. (1999). A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. *AIDS Res Hum Retroviruses* **15**(4), 395-8.
- VanCott, T. C., Mascola, J. R., Kaminski, R. W., Kalyanaraman, V., Hallberg, P. L., Burnett, P. R., Ulrich, J. T., Rechtman, D. J., and Birx, D. L. (1997). Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. *J Virol* **71**(6), 4319-30.
- Vanhems, P., Baratin, D., Allard, R., Marceillac, E., Biron, F., Cotte, L., and Saint-Marc, T. (1999). Factors associated with the time elapsed between the initial detection of HIV-1 antibodies and a diagnosis of AIDS among patients followed in Lyons University Hospitals. CISIH Collaborators. *Sex Transm Infect* **75**(6), 389-91.
- Weber, J., Fenyo, E. M., Beddows, S., Kaleebu, P., and Bjorndal, A. (1996). Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. *J Virol* **70**(11), 7827-32.
- Wee, E. G., Patel, S., McMichael, A. J., and Hanke, T. (2002). A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. *J Gen Virol* **83**(Pt 1), 75-80.
- Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., Komarova, N. L., Nowak, M. A., Hahn, B. H., Kwong, P. D., and Shaw, G. M. (2003). Antibody neutralization and escape by HIV-1. *Nature* **422**(6929), 307-12.

- Weissenhorn, W., Wharton, S. A., Calder, L. J., Earl, P. L., Moss, B., Aliprandis, E., Skehel, J. J., and Wiley, D. C. (1996). The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. *Embo J* **15**(7), 1507-14.
- Wild, C., Dubay, J. W., Greenwell, T., Baird, T., Jr., Oas, T. G., McDanal, C., Hunter, E., and Matthews, T. (1994a). Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. *Proc Natl Acad Sci U S A* **91**(26), 12676-80.
- Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994b). Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. *Proc Natl Acad Sci U S A* **91**(21), 9770-4.
- Williamson, C., Morris, L., Maughan, M. F., Ping, L. H., Dryga, S. A., Thomas, R., Reap, E. A., Cilliers, T., van Harmelen, J., Pascual, A., Ramjee, G., Gray, G., Johnston, R., Karim, S. A., and Swanstrom, R. (2003). Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. *AIDS Res Hum Retroviruses* **19**(2), 133-44.
- Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A. A., Desjardin, E., Newman, W., Gerard, C., and Sodroski, J. (1996). CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. *Nature* **384**(6605), 179-83.
- Wyatt, R., Desjardin, E., Olshevsky, U., Nixon, C., Binley, J., Olshevsky, V., and Sodroski, J. (1997). Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. *J Virol* **71**(12), 9722-31.
- Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A., and Sodroski, J. G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. *Nature* **393**(6686), 705-11.
- Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., and Sodroski, J. (1995). Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. *J Virol* **69**(9), 5723-33.
- Wyatt, R., and Sodroski, J. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. *Science* **280**(5371), 1884-8.
- Wyatt, R., Sullivan, N., Thali, M., Repke, H., Ho, D., Robinson, J., Posner, M., and Sodroski, J. (1993). Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. *J Virol* **67**(8), 4557-65.
- Xiang, S. H., Doka, N., Choudhary, R. K., Sodroski, J., and Robinson, J. E. (2002). Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. *AIDS Res Hum Retroviruses* **18**(16), 1207-17.
- Xu, W., Smith-Franklin, B. A., Li, P. L., Wood, C., He, J., Du, Q., Bhat, G. J., Kankasa, C., Katinger, H., Cavacini, L. A., Posner, M. R., Burton, D. R., Chou, T. C., and Ruprecht, R. M. (2001). Potent neutralization of primary human immunodeficiency

- virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. *J Hum Virol* **4**(2), 55-61.
- Yang, X., Wyatt, R., and Sodroski, J. (2001). Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. *J Virol* **75**(3), 1165-71.
- Yang, Z. Y., Chakrabarti, B. K., Xu, L., Welcher, B., Kong, W. P., Leung, K., Panet, A., Mascola, J. R., and Nabel, G. J. (2004). Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. *J Virol* **78**(8), 4029-36.
- Yarchoan, R., Redfield, R. R., and Broder, S. (1986). Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. *J Clin Invest* **78**(2), 439-47.
- Yates, J. L., Warren, N., and Sugden, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. *Nature* **313**(6005), 812-5.
- Yoshie, O., and Ono, Y. (1980). Anti-phosphorylcholine antibody-producing cells in human lymphoblastoid cell lines established by transformation with Epstein-Barr virus. *Cell Immunol* **56**(2), 305-16.
- Zhang, Y. J., Fracasso, C., Fiore, J. R., Bjorndal, A., Angarano, G., Gringeri, A., and Fenyo, E. M. (1997). Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. *J Infect Dis* **176**(5), 1180-7.
- Zimber-Strobl, U., and Strobl, L. J. (2001). EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. *Semin Cancer Biol* **11**(6), 423-34.
- Zolla-Pazner, S., O'Leary, J., Burda, S., Gorny, M. K., Kim, M., Mascola, J., and McCutchan, F. (1995). Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. *J Virol* **69**(6), 3807-15.
- Zwick, M. B., Labrijn, A. F., Wang, M., Spenlehauer, C., Saphire, E. O., Binley, J. M., Moore, J. P., Stiegler, G., Katinger, H., Burton, D. R., and Parren, P. W. (2001a). Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. *J Virol* **75**(22), 10892-905.
- Zwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton, D. R., and Parren, P. W. (2001b). Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. *J Virol* **75**(24), 12198-208.